1. [Hematology in the time of COVID-19].
- Author
-
Gavillet M, Rufer N, Grandoni F, Carr Klappert J, Zermatten MG, Cairoli A, Canellini G, Alberio L, Duchosal MA, Spertini O, and Blum S
- Subjects
- COVID-19, Hematologic Diseases diagnosis, Hematologic Diseases therapy, Hematology trends, Humans, SARS-CoV-2, Betacoronavirus, Coronavirus Infections complications, Coronavirus Infections epidemiology, Hematologic Diseases complications, Pandemics, Pneumonia, Viral complications, Pneumonia, Viral epidemiology
- Abstract
The COVID-19 pandemic impacts the hematology practice. Intensive chemotherapies for high-grade lymphomas and acute leukemias, multiple myeloma treatments and most hematopoietic stem cell transplantations should be performed as usual. Low-grade lymphomas should only be treated when strictly indicated, maintenance can be postponed. Other myeloid neoplasia and their therapies cause imunosupression; dose adjustment is recommended but no brisk stopping. Sickle cell anemia patients are highly succeptible to severe COVID-19 course. Thrombocytopenia and procoagulant state are associated with severe courses of COVID-19, requiring an individualized therapy. No data indicate a risk of SARS-CoV-2 transmission through blood product transfusion., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Published
- 2020